Pharmaceuticals | Hemlibra confirmed as a game changer

Hemlibra to dominate the haemophilia A market. This report follows a meeting we organised with a KOL to discuss new treatment opportunities for haemophilia, with a special focus on haemophilia A since it concerns around 85% of patients. Until now, the standard of care was to administer the lacking coagulation factor, FVIII (and FIX for haemophilia B). The main disadvantages with these factors is that they must be administered intravenously and at least twice a week. Our KOL has been won over by recently-launched Hemlibra, especially for patients with inhibitors. Not only is the drug more convenient with an SC injection up to once a month, but it's efficacy is also high, mainly in prophylaxis. Our guest KOL told us she would suggest that all her patients switch to Hemlibra even though she confirmed that some patients would be reluctant to do so because of the drug's novelty.